5858 HORTON STREET #455, EMERYVILLE, CA
Material disclosure
2026 Annual Meeting of Stockholders - Election of Class III Directors
Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
Annual Report to Security Holders
Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics Issues Pre-Funded Warrants for Common Stock
4D Molecular Therapeutics Reports $514 Million in Cash Position
Other Events
Q1
FY 2025
Q3
Q2
FY 2023
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement